Didactics-Sentinel Lymph Node Biopsy in Endometrial Cancer and its Value to Patients

Sentinel Lymph Node Biopsy in Endometrial Cancer and its Value to Patients

Video Transcription

Video Summary

Andreas Overmeyer’s presentation at the IGCS Eco-Tumor Board focused on the utility of sentinel lymph node biopsy in endometrial cancer. He explained that while sentinel node biopsy is recognized for its accuracy in identifying metastatic disease and reduces the number of nodes removed compared to systematic dissection, its overall value remains uncertain. This uncertainty exists due to questions about its effect on disease-free and overall survival, patient-reported outcomes, adjuvant treatment rates, and healthcare costs. Current studies confirm the biopsy's diagnostic precision, but lack robust data on patient-focused outcomes. To address this, Overmeyer introduced the ENDO3 trial: a phase three clinical trial comparing sentinel node biopsy with no lymph node dissection, aiming to evaluate comprehensive outcomes including survival, quality of life, and cost-effectiveness. The trial seeks to provide high-quality prospective data, filling the existing research gap and potentially influencing future treatment guidelines.

Asset Subtitle

Andreas Obermair and Helena Obermair
November 2021

Keywords

sentinel lymph node biopsy

endometrial cancer

ENDO3 trial

diagnostic precision

patient-focused outcomes

treatment guidelines